Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs Rs 977 crore in Q1FY23, while the generic business rose 19% to Rs 580 crore.Biocon said that its net profit and margins would have been much higher, had it not been for higher R&D and other expenses.